ZUG, Switzerland, May 07, 2025 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS / ICX: OCS.IC) (“Oculis”), a global biopharmaceutical company focused on innovations addressing ophthalmic and neuro-ophthalmic diseases with significant unmet medical needs, today announced that Oculis will be attending and presenting at the following upcoming investor conferences: Bio€quity EuropeMay 12-14, 2025; Bruges, BelgiumCompany update by Riad Sherif, MD, Chief Executive Officer, on May 14 at 11am CET Bank of America ...

公司动态 - Oculis Holding AG将参加并出席多个投资者会议包括Bio€quity Europe、Bank of America Healthcare Conference、H C Wainwright Annual BioConnect at Nasdaq和Stifel Virtual Ophthalmology Forum [1][2] - 公司首席执行官Riad Sherif MD将在Bio€quity Europe会议上进行公司更新演讲时间为2025年5月14日11点CET [1] - 首席财务官Sylvia Cheung将在Bank of America Healthcare Conference进行炉边谈话时间为2025年5月14日15点PT [2] - Sylvia Cheung还将在H C Wainwright Annual BioConnect at Nasdaq和Stifel Virtual Ophthalmology Forum分别进行公司更新和炉边谈话 [2] - 公司将在会议期间提供一对一会议机会投资者可通过赞助机构代表预约 [2] - 网络直播链接将在公司官网的"活动与演讲"页面发布 [3] 公司概况 - Oculis是一家专注于眼科和神经眼科疾病创新疗法的全球生物制药公司 [5] - 公司拥有多个差异化创新产品管线包括OCS-01(糖尿病性黄斑水肿)、Privosegtor(OCS-05)(急性视神经炎)和Licaminlimab(OCS-02)(干眼症) [5] - 公司总部位于瑞士在美国和冰岛设有运营机构 [5] - 公司由经验丰富的管理团队领导并得到国际领先医疗健康投资者的支持 [5]

ZUG, Switzerland, May 01, 2025 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS / ICX: OCS.IC) (“Oculis”), a global biopharmaceutical company focused on innovations addressing ophthalmic and neuro-ophthalmic diseases with significant unmet medical needs, today announced upcoming presentations highlighting its innovative late-stage pipeline at Eyecelerator 2025, the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting and the Retina World Congress (RWC). The presentation of the DME AW ...

ZUG, Switzerland, May 01, 2025 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS / ICX: OCS.IC) (“Oculis”), a global biopharmaceutical company focused on innovations addressing ophthalmic and neuro-ophthalmic diseases with significant unmet medical needs, today announced upcoming presentations highlighting its innovative late-stage pipeline at Eyecelerator 2025, the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting and the Retina World Congress (RWC). The presentation of the DME AW ...

ZUG, Switzerland, April 25, 2025 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS; XICE: OCS) (“Oculis” or the “Company”), a global biopharmaceutical company, has issued registered ordinary shares of the Company, each with a nominal value of CHF 0.01. The issuance comprises 589,974 registered shares, reflecting the settlement of 310,941 shares issued in connection with the exercise of equity awards under the Company’s Stock Option and Incentive Plan Regulation and 279,033 shares issued through EBAC warran ...

ZUG, Switzerland, April 17, 2025 (GLOBE NEWSWIRE) -- Oculis Holding AG (NASDAQ:OCS) ("Oculis"), a global biopharmaceutical company focused on innovations addressing ophthalmic and neuro-ophthalmic diseases with significant unmet medical needs, today announces, in collaboration with EURETINA, the 2025 Ramin Tadayoni Award. The Ramin Tadayoni Award continues its legacy through EURETINA and has been supported by Oculis as a lasting tribute to Professor Tadayoni, the Company's Chief Scientific Officer and a wor ...

ZUG, Switzerland, April 15, 2025 (GLOBE NEWSWIRE) -- Oculis Holding AG (NASDAQ:OCS) ("Oculis" or the "Company"), a global biopharmaceutical company focused on innovations addressing ophthalmic and neuro-ophthalmic diseases with significant unmet medical needs, will host an in-person and virtual R&D Day today, Tuesday, April 15, 2025 from 10:00 AM to 12:00 PM ET at the Intercontinental New York Barclay hotel. To attend the event or participate virtually, please register here. The event will provide an update ...

ZUG, Switzerland, April 15, 2025 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS / XICE: OCS) (“Oculis” or the “Company"), a global biopharmaceutical company focused on innovations addressing ophthalmic and neuro-ophthalmic diseases with significant unmet medical needs, will host an in-person and virtual R&D Day today, Tuesday, April 15, 2025 from 10:00 AM to 12:00 PM ET at the Intercontinental New York Barclay hotel. To attend the event or participate virtually, please register here. The event will prov ...

DIAMOND is the first and only pivotal trial program ever conducted with a topical treatment for diabetic macular edema (DME)Over 800 patients randomized in DIAMOND-1 or DIAMOND-2 Phase 3 trials at an industry-leading record speed across 119 sites worldwide primarily in the US; topline data readout expected in Q2 2026 with NDA submission to followCompany to provide an update on the DIAMOND program and its innovative late-stage pipeline at the upcoming in-person and virtual R&D Day on Tuesday, April 15 ZUG, S ...

ZUG, Switzerland, April 10, 2025 (GLOBE NEWSWIRE) -- DIAMOND is the first and only pivotal trial program ever conducted with a topical treatment for diabetic macular edema (DME)Over 800 patients randomized in DIAMOND-1 or DIAMOND-2 Phase 3 trials at an industry-leading record speed across 119 sites worldwide primarily in the US; topline data readout expected in Q2 2026 with NDA submission to followCompany to provide an update on the DIAMOND program and its innovative late-stage pipeline at the upcoming in-p ...